Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of November 2023, specifically dated November 29, 2023. The report serves to disseminate two press releases regarding clinical outcomes and regulatory approvals to U.S. investors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational milestones and regulatory updates rather than financial performance data.
Material Changes and Operational Updates
- Clinical Success: On November 28, 2023, the Company announced that its IceCure System successfully treated a kidney cancer tumor, achieving a 92% disease-free survival rate and a 100% secondary local control rate.
- Regulatory Expansion: On November 29, 2023, the Company reported that its ProSense system has deepened regulatory approval in India.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the associated press releases (Exhibits 99.1 and 99.2) by reference into the Company's Registration Statements on Form F-3 and Form S-8. The text does not contain specific numerical guidance or detailed risk factors within the body of this summary report, deferring to the full exhibits for such disclosures.
Investor Verification Checklist
- Verify the full details of the kidney cancer treatment study in Exhibit 99.1, including sample size and study duration.
- Confirm the specific scope and commercial implications of the ProSense regulatory approval in India as detailed in Exhibit 99.2.
- Review the "Forward Looking Statements" sections in the exhibits for potential risks related to future clinical trials and market expansion.